117 related articles for article (PubMed ID: 21062644)
21. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
22. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
23. Modeling Huntington's disease in cells, flies, and mice.
Sipione S; Cattaneo E
Mol Neurobiol; 2001 Feb; 23(1):21-51. PubMed ID: 11642542
[TBL] [Abstract][Full Text] [Related]
24. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
[TBL] [Abstract][Full Text] [Related]
26. Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.
Orrú M; Zanoveli JM; Quiroz C; Nguyen HP; Guitart X; Ferré S
Exp Neurol; 2011 Nov; 232(1):76-80. PubMed ID: 21867705
[TBL] [Abstract][Full Text] [Related]
27. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
28. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
29. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
30. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
31. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
Sadri-Vakili G; Menon AS; Farrell LA; Keller-McGandy CE; Cantuti-Castelvetri I; Standaert DG; Augood SJ; Yohrling GJ; Cha JH
Eur J Neurosci; 2006 Jun; 23(12):3171-5. PubMed ID: 16820007
[TBL] [Abstract][Full Text] [Related]
32. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
Oliveira JM
J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
[TBL] [Abstract][Full Text] [Related]
33. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
34. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
Popoli P; Blum D; Domenici MR; Burnouf S; Chern Y
Curr Pharm Des; 2008; 14(15):1500-11. PubMed ID: 18537673
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein levels modulate Huntington's disease in mice.
Corrochano S; Renna M; Carter S; Chrobot N; Kent R; Stewart M; Cooper J; Brown SD; Rubinsztein DC; Acevedo-Arozena A
Hum Mol Genet; 2012 Feb; 21(3):485-94. PubMed ID: 22010050
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
37. A new drug design targeting the adenosinergic system for Huntington's disease.
Huang NK; Lin JH; Lin JT; Lin CI; Liu EM; Lin CJ; Chen WP; Shen YC; Chen HM; Chen JB; Lai HL; Yang CW; Chiang MC; Wu YS; Chang C; Chen JF; Fang JM; Lin YL; Chern Y
PLoS One; 2011; 6(6):e20934. PubMed ID: 21713039
[TBL] [Abstract][Full Text] [Related]
38. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease.
Varani K; Abbracchio MP; Cannella M; Cislaghi G; Giallonardo P; Mariotti C; Cattabriga E; Cattabeni F; Borea PA; Squitieri F; Cattaneo E
FASEB J; 2003 Nov; 17(14):2148-50. PubMed ID: 12958155
[TBL] [Abstract][Full Text] [Related]
39. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.
Cha JH; Frey AS; Alsdorf SA; Kerner JA; Kosinski CM; Mangiarini L; Penney JB; Davies SW; Bates GP; Young AB
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):981-9. PubMed ID: 10434296
[TBL] [Abstract][Full Text] [Related]
40. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
